About Prosensa
Prosensa is a company based in Leiden (Netherlands) founded in 2002 was acquired by BioMarin Pharmaceutical in November 2014.. Prosensa has raised $72.62 million across 4 funding rounds from investors including BioMarin Pharmaceutical, Idinvest Partners and Gimv. Prosensa operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Denali Therapeutics, Neurocrine and PTC Therapeutics, among others.
- Headquarter Leiden, Netherlands
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Prosensa Holding N.V.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$72.62 M (USD)
in 4 rounds
-
Latest Funding Round
$200 K (USD), Grant
Jun 27, 2014
-
Investors
BioMarin Pharmaceutical
& 7 more
-
Employee Count
Employee Count
-
Acquired by
BioMarin Pharmaceutical
(Nov 24, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Prosensa
Prosensa has successfully raised a total of $72.62M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $200 thousand completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $200,000
-
First Round
First Round
(01 Feb 2007)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2014 | Amount | Grant - Prosensa | Valuation |
investors |
|
| Jan, 2012 | Amount | Series C - Prosensa | Valuation | New Enterprise Associates | |
| Dec, 2008 | Amount | Series B - Prosensa | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Prosensa
Prosensa has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include BioMarin Pharmaceutical, Idinvest Partners and Gimv. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
Private equity firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Prosensa
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Prosensa
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Prosensa Comparisons
Competitors of Prosensa
Prosensa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Denali Therapeutics, Neurocrine and PTC Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Prosensa
Frequently Asked Questions about Prosensa
When was Prosensa founded?
Prosensa was founded in 2002 and raised its 1st funding round 5 years after it was founded.
Where is Prosensa located?
Prosensa is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Is Prosensa a funded company?
Prosensa is a funded company, having raised a total of $72.62M across 4 funding rounds to date. The company's 1st funding round was a Series B of $24.7M, raised on Feb 01, 2007.
What does Prosensa do?
Prosensa was founded in 2002 in Leiden, Netherlands, within the biotechnology sector. Focus was placed on RNA-modulating therapeutics for neuromuscular disorders, including the lead compound drisapersen, an oligonucleotide targeting dystrophin RNA splicing for Duchenne muscular dystrophy across seven programs. Preclinical candidates were advanced for Huntingtons disease and myotonic dystrophy. Acquisition by BioMarin occurred in November 2014.
Who are the top competitors of Prosensa?
Prosensa's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Who are Prosensa's investors?
Prosensa has 8 investors. Key investors include BioMarin Pharmaceutical, Idinvest Partners, Gimv, Abingworth, and Life Sciences Partners.